title: Negative fetal fibronectin: who is still treating for threatened preterm labor and does it help?
abstract: OBJECTIVE
  Fetal fibronectin (fFN) has a high negative predictive value for delivery in the next seven days in patients at risk for preterm birth. Providers sometimes disregard a negative result and manage the patient for threatened preterm labor. Our objective was to identify the rate at which patients with a negative fFN were managed for threatened preterm labor and if delivery outcomes were improved with such management.
  
  
  METHODS
  Retrospective chart review of 111 patients at a single institution evaluated in the obstetrical triage unit for symptoms of threatened preterm labor with negative fFN results over a 19-month period between November 2004 and June 2006. Charts were reviewed for baseline patient characteristics such as gestational age at presentation to triage and fFN testing, prior obstetrical history, cervical examination and contraction frequency. Gestational age at delivery was documented. Rates of admission to the hospital and treatments for threatened preterm labor in this cohort were reviewed.
  
  
  RESULTS
  Thirty-seven of patients (33%) with a negative fFN result were managed for threatened preterm labor (admitted to the hospital, given tocolytics, steroids, or intravenous antibiotics) by their provider. Patients undergoing these interventions were more likely to have cervical dilatation, effacement and were contracting more frequently. Only one of the patients delivered within 7 or 14 days of fFN testing. There was no advantage seen to management of threatened preterm labor in the setting of a negative fFN in terms of pregnancy prolongation, even when analyzing the patients with meaningful clinical findings (dilated 2 cm, effaced >or=80%, or contracting >or=12 times/h).
  
  
  CONCLUSIONS
  Patients with meaningful clinical findings suspicious for preterm labor are more likely to undergo interventions by their physicians in the face of a negative fFN. This management does not improve length of gestation.
authors.affiliation: Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, USA. lip9014@med.cornell.edu
authors.forename: Linda M
authors.initials: LM
authors.lastname: Peláez
authors.forename: Nathan S
authors.initials: NS
authors.lastname: Fox
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Chasen
mesh_terms: D000328:Adult; D002582:Cervix Mucus / Q000737:chemistry; D005260:Female; D005353:Fibronectins / Q000032:analysis*; D006801:Humans; D008485:Medical Audit; D007752:Obstetric Labor, Premature / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control; D012189:Retrospective Studies
chemical_list: D005353:Fibronectins